News and Announcements
LETTER TO EDITOR
Exploring the potential of new combination therapy strategies in advanced gastric cancer
Show Less
1
Department of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin,
China
2
Tianjin Key Laboratory of Modern Chinese Medicine Theory of Innovation and Application, Tianjin University of Traditional Chinese Medicine, Tianjin,
China
EJMO, 8594 https://doi.org/10.36922/ejmo.8594
Submitted: 18 January 2025 | Accepted: 11 February 2025 | Published: 20 February 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Conflict of interest
The authors declare they have no competing interests.
References
- Guan WL, He Y, Xu RH. Gastric cancer treatment: Recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. doi: 10.1186/s13045-023-01451-3
- Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648. doi: 10.1016/s0140-6736(20)31288-5
- Akbas S, Alan O, Kuvvet BB, Lacin S, Köylü B, Selcukbiricik F. Nivolumab, ramucirumab and paclitaxel combination as second line therapy for advanced stage gastric cancer. EJMO. 2024;8(4):488-495. doi: 10.14744/ejmo.2024.40834
- Nakajima TE, Kadowaki S, Minashi K, et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27(4):1029-1036. doi: 10.1158/1078-0432.Ccr-20-3559
- Depotte L, Palle J, Rasola C, et al. New developments and standard of care in the management of advanced gastric cancer. Clin Res Hepatol Gastroenterol. 2024;48(1):102245. doi: 10.1016/j.clinre.2023.102245
- Izawa N, Ohta S, Kadowaki S, et al. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC). Ann Oncol. 2020;31:S282-S283. doi: 10.1016/j.annonc.2020.08.225
- Thuss-Patience P, Högner A, Goekkurt E, et al. Ramucirumab, avelumab, and paclitaxel as second-line treatment in esophagogastric adenocarcinoma: The phase 2 RAP (AIO-STO-0218) nonrandomized controlled trial. JAMA Netw Open. 2024;7(1):e2352830. doi: 10.1001/jamanetworkopen.2023.52830
- Ye HN, Liu XY, Qin BL. Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer. World J Gastrointest Oncol. 2023;15(1):69-75. doi: 10.4251/wjgo.v15.i1.69
- Tan Y, Wang H, Xu B, et al. Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response. Front Pharmacol. 2022;13:977708. doi: 10.3389/fphar.2022.977708
- Kong X, Li Q, Wang D, Wang M, Yang F, Meng J. Mechanism of qizhen decoction-mediated maturation of DC cells to activate the IL-12/JAK2/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer. J Ethnopharmacol. 2024;320:117399. doi: 10.1016/j.jep.2023.117399